. Author manuscript; available in PMC: 2018 Jan 1.

Published in final edited form as: Trans R Soc Trop Med Hyg. 2017 Mar 18;111(1):12–17. doi: 10.1093/trstmh/trx011

Table 1.

Country programmes considered for the calculation of the reduction of the proportion of STH infection of moderate and heavy intensity after preventive chemotherapy

Country	Year	Drug*	Number of people surveyed at baseline	Individuals with STH infections of moderate high intensity baseline – last follow-up			Follow up (months)	Age group	PC frequency	Ref
Country	Year	Drug*	Number of people surveyed at baseline	A. lumbricoides	T trichiura	hookworms	Follow up (months)	Age group	PC frequency	Ref
Myanmar	2004	Alb	1 000	18% - 7%			84	SAC	2/year	10, 11
Myanmar	2013	Alb	1 000	18% - 7%			84	SAC	2/year	10, 11
Bangladesh	2005	Alb	792	29.4% - 1.8%	12.4% - 1.1%	NA	60	SAC	2/year	12, 13
Bangladesh	2016	Alb	792	29.4% - 1.8%	12.4% - 1.1%	NA	60	SAC	2/year	12, 13
Lao	2008	Meb	2 885	37.8% - 9.2%	10.3% - 3.8%	NA	24	SAC	2/year	14
Tanzania	2009	Alb	1 194	23% - 1.4%	24% - 0.3%	26% - 0	132	SAC	1/year	15
Viet Nam	2013	Alb	389	8% - 0	2% - 0	14% - 0	12, 30, 54	WCBA	2/year	16
Cuba	2014	Meb	268	6.7% - 1%	NA	NA	36	SAC	2/year	17
Peru	2016	Meb	816	40% - 2.9%	25.2% - 6.7%	NA	12, 24	SAC	3/year	18
Kenya	2016	Alb	21 432	8.2% - 5.4%	8.2% - 0.3%	NA	36	SAC	1/year	19

Alb= albendazole; Meb= mebendazole; PC= preventive chemotherapy SAC = School aged children, WCBA=Women of Child bearing age, NA (prevalence of MHI 0-3%)